These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 20813141)

  • 1. Identification of inhibitors for putative malaria drug targets among novel antimalarial compounds.
    Crowther GJ; Napuli AJ; Gilligan JH; Gagaring K; Borboa R; Francek C; Chen Z; Dagostino EF; Stockmyer JB; Wang Y; Rodenbough PP; Castaneda LJ; Leibly DJ; Bhandari J; Gelb MH; Brinker A; Engels IH; Taylor J; Chatterjee AK; Fantauzzi P; Glynne RJ; Van Voorhis WC; Kuhen KL
    Mol Biochem Parasitol; 2011 Jan; 175(1):21-9. PubMed ID: 20813141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Collateral Sensitivity to Dihydroorotate Dehydrogenase Inhibitors in Plasmodium falciparum.
    Ross LS; Lafuente-Monasterio MJ; Sakata-Kato T; Mandt REK; Gamo FJ; Wirth DF; Lukens AK
    ACS Infect Dis; 2018 Apr; 4(4):508-515. PubMed ID: 29336544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification via a Parallel Hit Progression Strategy of Improved Small Molecule Inhibitors of the Malaria Purine Uptake Transporter that Inhibit
    Sosa Y; Deniskin R; Frame IJ; Steiginga MS; Bandyopadhyay D; Graybill TL; Kallal LA; Ouellette MT; Pope AJ; Widdowson KL; Young RJ; Akabas MH
    ACS Infect Dis; 2019 Oct; 5(10):1738-1753. PubMed ID: 31373203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility of Plasmodium falciparum to glutamate dehydrogenase inhibitors--a possible new antimalarial target.
    Aparicio IM; Marín-Menéndez A; Bell A; Engel PC
    Mol Biochem Parasitol; 2010 Aug; 172(2):152-5. PubMed ID: 20399810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-throughput screening for small-molecule inhibitors of plasmodium falciparum glucose-6-phosphate dehydrogenase 6-phosphogluconolactonase.
    Preuss J; Hedrick M; Sergienko E; Pinkerton A; Mangravita-Novo A; Smith L; Marx C; Fischer E; Jortzik E; Rahlfs S; Becker K; Bode L
    J Biomol Screen; 2012 Jul; 17(6):738-51. PubMed ID: 22496096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target identification and validation of novel antimalarials.
    McNamara C; Winzeler EA
    Future Microbiol; 2011 Jun; 6(6):693-704. PubMed ID: 21707315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway.
    Fletcher S; Avery VM
    Malar J; 2014 Aug; 13():343. PubMed ID: 25174342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Yeast-based high-throughput screen identifies Plasmodium falciparum equilibrative nucleoside transporter 1 inhibitors that kill malaria parasites.
    Frame IJ; Deniskin R; Rinderspacher A; Katz F; Deng SX; Moir RD; Adjalley SH; Coburn-Flynn O; Fidock DA; Willis IM; Landry DW; Akabas MH
    ACS Chem Biol; 2015 Mar; 10(3):775-83. PubMed ID: 25602169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-Myristoylation as a Drug Target in Malaria: Exploring the Role of N-Myristoyltransferase Substrates in the Inhibitor Mode of Action.
    Schlott AC; Holder AA; Tate EW
    ACS Infect Dis; 2018 Apr; 4(4):449-457. PubMed ID: 29363940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased Ca
    Kushwaha AK; Apolis L; Ito D; Desai SA
    Cell Microbiol; 2018 Sep; 20(9):e12853. PubMed ID: 29726084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmodium falciparum Choline Kinase Inhibition Leads to a Major Decrease in Phosphatidylethanolamine Causing Parasite Death.
    Serrán-Aguilera L; Denton H; Rubio-Ruiz B; López-Gutiérrez B; Entrena A; Izquierdo L; Smith TK; Conejo-García A; Hurtado-Guerrero R
    Sci Rep; 2016 Sep; 6():33189. PubMed ID: 27616047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective and specific inhibition of the plasmodium falciparum lysyl-tRNA synthetase by the fungal secondary metabolite cladosporin.
    Hoepfner D; McNamara CW; Lim CS; Studer C; Riedl R; Aust T; McCormack SL; Plouffe DM; Meister S; Schuierer S; Plikat U; Hartmann N; Staedtler F; Cotesta S; Schmitt EK; Petersen F; Supek F; Glynne RJ; Tallarico JA; Porter JA; Fishman MC; Bodenreider C; Diagana TT; Movva NR; Winzeler EA
    Cell Host Microbe; 2012 Jun; 11(6):654-63. PubMed ID: 22704625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the Plasmodium vivax equilibrative nucleoside transporter 1 (PvENT1) for antimalarial drug development.
    Deniskin R; Frame IJ; Sosa Y; Akabas MH
    Int J Parasitol Drugs Drug Resist; 2016 Apr; 6(1):1-11. PubMed ID: 26862473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A New Set of Chemical Starting Points with Plasmodium falciparum Transmission-Blocking Potential for Antimalarial Drug Discovery.
    Almela MJ; Lozano S; Lelièvre J; Colmenarejo G; Coterón JM; Rodrigues J; Gonzalez C; Herreros E
    PLoS One; 2015; 10(8):e0135139. PubMed ID: 26317851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational and experimental elucidation of Plasmodium falciparum phosphoethanolamine methyltransferase inhibitors: Pivotal drug target.
    Singh J; Vijay S; Mansuri R; Rawal R; Kadian K; Sahoo GC; Kumar M; Sharma A
    PLoS One; 2019; 14(8):e0221032. PubMed ID: 31437171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a Novel High-Density [3H]Hypoxanthine Scintillation Proximity Assay To Assess Plasmodium falciparum Growth.
    de Cózar C; Caballero I; Colmenarejo G; Sanz LM; Álvarez-Ruiz E; Gamo FJ; Cid C
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5949-56. PubMed ID: 27458216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Dual-Stage Malaria Inhibitors with New Targets.
    Raphemot R; Lafuente-Monasterio MJ; Gamo-Benito FJ; Clardy J; Derbyshire ER
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1430-7. PubMed ID: 26666931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Fluorescence Resonance Energy Transfer-Based Screen in High-Throughput Format To Identify Inhibitors of Malarial and Human Glucose Transporters.
    Kraft TE; Heitmeier MR; Putanko M; Edwards RL; Ilagan MX; Payne MA; Autry JM; Thomas DD; Odom AR; Hruz PW
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7407-7414. PubMed ID: 27736766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computational identification of Plasmodium falciparum RNA pseudouridylate synthase as a viable drug target, its physicochemical properties, 3D structure prediction and prediction of potential inhibitors.
    Afolabi R; Chinedu S; Ajamma Y; Adam Y; Koenig R; Adebiyi E
    Infect Genet Evol; 2022 Jan; 97():105194. PubMed ID: 34968763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmodium falciparum: new molecular targets with potential for antimalarial drug development.
    Gardiner DL; Skinner-Adams TS; Brown CL; Andrews KT; Stack CM; McCarthy JS; Dalton JP; Trenholme KR
    Expert Rev Anti Infect Ther; 2009 Nov; 7(9):1087-98. PubMed ID: 19883329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.